We further validated that SLC7A6 was significantly up-regulated in cisplatin resistant bladder cancer cells versus cisplatin sensitive bladder cancer cells while the expression of SLC7A6 in CD8 + T cells remained relatively at minimum level. This evidence concerns the gene CD8A and urinary bladder cancer.